---
figid: PMC3375400__fendo-03-00076-g001
figlink: /pmc/articles/PMC3375400/figure/F1/
number: F1
caption: Comparison of the pathways responsible for the anti-apoptotic and pro-apoptotic
  effects of immune complexes containing oxidized LDL (oxLDL-IC) and malondialdehyde-modified
  LDL (MDA-LDL-IC). OxLDL-IC activate cell proliferation pathways through Syk, a pathway
  that leads to activation of Akt and NFkB. The activation of Akt leads prevents the
  inactivation of anti-apototic gene products (Bcl-xL in the diagram). S1P-mediated
  activation of Akt and proliferation genes has been suggested by previously published
  data from our group (Hammad et al., ). This could result from the direct activation
  of SK1 by Syk, or as a consequence of the release of growth factors, upon ligation
  of the corresponding receptor, which activate S1k via PKC. As for the pro-apoptotic
  properties of MDA-LDL-IC, two possible pathways could be involved. One would result
  from the simultaneous activation of SK2 (whose phosphorylation is less stable than
  that of SK1) and S1PP. This would result in a reduced generation of S1P, and accumulation
  of ceramides, which in turn would inhibit anti-apoptotic genes (Bcl-2 in the diagram)
  and allow the activation of the pro-apoptotic intrinsic pathway. An alternative
  (and not exclusive) pathway to reach the same effect would involve the degradation
  of internalized MDA and release of highly charged phospholipids whose interaction
  with a CD36-TLR2 complex would activate the generation of ROS and increased cellular
  stress.
pmcid: PMC3375400
papertitle: The Pathogenic Role of the Adaptive Immune Response to Modified LDL in
  Diabetes.
reftext: Gabriel Virella, et al. Front Endocrinol (Lausanne). 2012;3:76.
pmc_ranked_result_index: '162279'
pathway_score: 0.9559671
filename: fendo-03-00076-g001.jpg
figtitle: Comparison of the pathways responsible for the anti-apoptotic and pro-apoptotic
  effects of immune complexes containing oxidized LDL (oxLDL-IC) and malondialdehyde-modified
  LDL (MDA-LDL-IC)
year: '2012'
organisms:
- Homo sapiens
ndex: bb979178-dee9-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3375400__fendo-03-00076-g001.html
  '@type': Dataset
  description: Comparison of the pathways responsible for the anti-apoptotic and pro-apoptotic
    effects of immune complexes containing oxidized LDL (oxLDL-IC) and malondialdehyde-modified
    LDL (MDA-LDL-IC). OxLDL-IC activate cell proliferation pathways through Syk, a
    pathway that leads to activation of Akt and NFkB. The activation of Akt leads
    prevents the inactivation of anti-apototic gene products (Bcl-xL in the diagram).
    S1P-mediated activation of Akt and proliferation genes has been suggested by previously
    published data from our group (Hammad et al., ). This could result from the direct
    activation of SK1 by Syk, or as a consequence of the release of growth factors,
    upon ligation of the corresponding receptor, which activate S1k via PKC. As for
    the pro-apoptotic properties of MDA-LDL-IC, two possible pathways could be involved.
    One would result from the simultaneous activation of SK2 (whose phosphorylation
    is less stable than that of SK1) and S1PP. This would result in a reduced generation
    of S1P, and accumulation of ceramides, which in turn would inhibit anti-apoptotic
    genes (Bcl-2 in the diagram) and allow the activation of the pro-apoptotic intrinsic
    pathway. An alternative (and not exclusive) pathway to reach the same effect would
    involve the degradation of internalized MDA and release of highly charged phospholipids
    whose interaction with a CD36-TLR2 complex would activate the generation of ROS
    and increased cellular stress.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BAD
  - AKT3
  - ARAF
  - RAF1
  - AKT2
  - SYK
  - AKT1
  - PLCD4
  - PLCG2
  - PRKD3
  - PLCG1
  - TLR2
  - MBTPS1
  - PLCB3
  - PLCB4
  - PLCB2
  - PRKCZ
  - PRKCI
  - BRAF
  - PLCD1
  - PRKCQ
  - BCL2
  - CASP1
  - PRKCA
  - KRAS
  - NRAS
  - PLCZ1
  - CASP4
  - CASP5
  - CASP3
  - CASP12
  - PRKCE
  - CASP6
  - PRKCB
  - CASP14
  - NFKB2
  - HRAS
  - PLCE1
  - CASP2
  - PRKCD
  - REL
  - RELA
  - PLCD3
  - PRKCH
  - CASP8
  - BCL2L1
  - MAPK1
  - PLCB1
  - NFKB1
  - RELB
  - MAPK3
  - CASP10
  - CASP7
  - PRKCG
  - CD36
  - CASP9
  - Cancer
genes:
- word: Bad
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: SYK
  symbol: SYK
  source: hgnc_symbol
  hgnc_symbol: SYK
  entrez: '6850'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD4
  entrez: '84812'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: TLR2
  symbol: TLR2
  source: hgnc_symbol
  hgnc_symbol: TLR2
  entrez: '7097'
- word: S1P
  symbol: S1P
  source: hgnc_alias_symbol
  hgnc_symbol: MBTPS1
  entrez: '8720'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB3
  entrez: '5331'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB4
  entrez: '5332'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB2
  entrez: '5330'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD1
  entrez: '5333'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: Bcl-2
  symbol: Bcl-2
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP1
  entrez: '834'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCZ1
  entrez: '89869'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP4
  entrez: '837'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP5
  entrez: '838'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP3
  entrez: '836'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP12
  entrez: '100506742'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP6
  entrez: '839'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP14
  entrez: '23581'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCE1
  entrez: '51196'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP2
  entrez: '835'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD3
  entrez: '113026'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP8
  entrez: '841'
- word: Bcl-xL
  symbol: bcl-xL
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2L1
  entrez: '598'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB1
  entrez: '23236'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP10
  entrez: '843'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP7
  entrez: '840'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: CD36
  symbol: CD36
  source: hgnc_symbol
  hgnc_symbol: CD36
  entrez: '948'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP9
  entrez: '842'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC3375400__F1
redirect_from: /figures/PMC3375400__F1
figtype: Figure
---
